Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2012

Open Access 01-12-2012 | Research article

Elevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patients

Authors: Xiaoxin Jiang, Ju-Fang Huang, Zhi Huo, Qiuqui Zhang, Yan Jiang, Xiaoping Wu, Yanwen Li, Guanmin Jiang, Leping Zeng, Xiao-Xin Yan, Ping Yu, Renxian Cao

Published in: BMC Immunology | Issue 1/2012

Login to get access

Abstract

Background

Elevation of soluble major histocompatibility complex class I chain-related gene A (sMICA) products in serum has been linked to tissue/organ transplantation, autoimmune diseases and some malignant disorders. Cells infected by microbiological pathogens may release sMICA, whereas less is known whether and to what extent serum sMICA levels may change in infectious diseases.

Methods

The present study determined serum sMICA levels by enzyme-linked immunosorbent assay (ELISA) in a southern China population, including patients (n = 1041) suffering from several types of malignant and infectious diseases and healthy controls (n = 141).

Results

Relative to controls, serum sMICA elevation was significant in patients of hepatic cancer, and was approaching statistical significance in patients with lung, gastric and nasopharyngeal cancers. sMICA elevation was also associated with some bacterial (Enterobacteriaceae, Mycobacterium tuberculosis, non-fermenting Gram-negative bacteria and Gram-positive cocci), viral (hepatitis B and C) and the Microspironema pallidum infections.

Conclusion

Serum sMICA levels may be informative for the diagnosis of some malignant and infectious diseases. The results also indicate that microbiological infections should be considered as a potential confounding clinical condition causing serum sMICA elevation while using this test to evaluate the status of other disorders, such as cancers, host-graft response and autoimmune diseases.
Appendix
Available only for authorised users
Literature
1.
Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002, 419: 734-738. 10.1038/nature01112.PubMedCrossRef
2.
Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001, 2: 255-260. 10.1038/85321.PubMedCrossRef
3.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA. Science. 1999, 285: 727-729. 10.1126/science.285.5428.727.PubMedCrossRef
4.
Tieng V, Le Bouguénec C, du Merle L, Bertheau P, Desreumaux P, Janin A, Charron D, Toubert A: Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA. 2002, 99: 2977-2982. 10.1073/pnas.032668099.PubMedPubMedCentralCrossRef
5.
Shiina T, Tamiya G, Oka A, Takishima N, Inoko H: Genome sequencing analysis of the 1.8 Mb entire human MHC class I region. Immunol Rev. 1999, 167: 193-199. 10.1111/j.1600-065X.1999.tb01392.x.PubMedCrossRef
6.
Bahram S, Shiina T, Oka A, Tamiya G, Inoko H: Genomic structure of the human MHC class I MICB gene. Immunogenetics. 1996, 45: 161-162. 10.1007/s002510050184.PubMedCrossRef
7.
Kulski JK, Dunn DS, Hui J, Martinez P, Romphruk AV, Leelayuwat C, Tay GK, Oka A, Inoko H: Alu polymorphism within the MICB gene and association with HLA-B alleles. Immunogenetics. 2002, 53: 975-979. 10.1007/s00251-001-0409-5.PubMedCrossRef
8.
Ando H, Mizuki N, Ota M, Yamazaki M, Ohno S, Goto K, Miyata Y, Wakisaka K, Bahram S, Inoko H: Allelic variants of the human MHC class I chain-related B gene (MICB). Immunogenetics. 1997, 46: 499-508. 10.1007/s002510050311.PubMedCrossRef
9.
Visser CJ, Tilanus MG, Schaeffer V, Tatari Z, Tamouza R, Janin A, Charron D: Sequencing-based typing reveals six novel MHC class I chain-related gene B (MICB) alleles. Tissue Antigens. 1998, 51: 649-652. 10.1111/j.1399-0039.1998.tb03008.x.PubMedCrossRef
10.
Fischer G, Argüello JR, Pérez-Rodríguez M, McWhinnie A, Marsh SG, Travers PJ, Madrigal JA: Sequence-specific oligonucleotide probing for MICB alleles reveals associations with MICA and HLA-B. Immunogenetics. 2000, 51: 591-599. 10.1007/s002510000179.PubMedCrossRef
11.
Glas J, Martin K, Brünnler G, Kopp R, Folwaczny C: MICA, MICB and C1_4_1 polymorphism in Crohn’s disease and ulcerative colitis. Tissue Antigens. 2001, 58: 243-249. 10.1034/j.1399-0039.2001.580404.x.PubMedCrossRef
12.
Liu X, Tian W, Li L, Cai J: Characterization of the major histocompatibility complex class I chain-related gene B (MICB) polymorphism in a northern Chinese Han population: the identification of a new MICB allele, MICB*023. Hum Immunol. 2011, 72: 727-732. 10.1016/j.humimm.2011.05.013.PubMedCrossRef
13.
Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, Yamazaki M, Watanabe K, Goto K, Nakamura S, Bahram S, Inoko H: Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci USA. 1997, 94: 1298-1303. 10.1073/pnas.94.4.1298.PubMedPubMedCentralCrossRef
14.
Karacki PS, Gao X, Thio CL, Thomas DL, Goedert JJ, Vlahov D, Kaslow RA, Strathdee S, Hilgartner MW, O’Brien SJ, Carrington M: MICA and recovery from hepatitis C virus and hepatitis B virus infections. Genes Immun. 2004, 5: 261-266. 10.1038/sj.gene.6364065.PubMedCrossRef
15.
Liu CJ, Lui MT, Chen HL, Lin SC, Chang KW: MICA and MICB overexpression in oral squamous cell carcinoma. J Oral Pathol Med. 2007, 36: 43-47.PubMedCrossRef
16.
Mei B, Luo Q, Du K, Huo Z, Wang F, Yu P: Association of MICA gene polymorphisms with Chlamydia trachomatis infection and related tubal pathology in infertile women. Hum Reprod. 2009, 24: 3090-3095. 10.1093/humrep/dep339.PubMedCrossRef
17.
Zou Y, Stastny P, Süsal C, Döhler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007, 357: 1293-1300. 10.1056/NEJMoa067160.PubMedCrossRef
18.
Zou Y, Yang X, Jiang X, Wang H, Hao Q, Liu Y, Yu P: High levels of soluble major histocompatibility complex class I related chain A (MICA) are associated with biliary cast syndrome after liver transplantation. Transpl Immunol. 2009, 21: 210-214. 10.1016/j.trim.2009.06.003.PubMedCrossRef
19.
Choy MK, Phipps ME: MICA polymorphism: biology and importance in immunity and disease. Trends Mol Med. 2010, 16: 97-106. 10.1016/j.molmed.2010.01.002.PubMedCrossRef
20.
Jiang X, Zou Y, Huo Z, Yu P: Association of major histocompatibility complex class I chain-related gene A microsatellite polymorphism and hepatocellular carcinoma in South China Han population. Tissue Antigens. 2011, 78: 143-147. 10.1111/j.1399-0039.2011.01693.x.PubMedCrossRef
21.
Luo QZ, Lin L, Gong Z, Mei B, Xu YJ, Huo Z, Yu P: Positive association of major histocompatibility complex class I chain-related gene A polymorphism with leukemia susceptibility in the people of Han nationality of Southern China. Tissue Antigens. 2011, 78: 178-184. 10.1111/j.1399-0039.2011.01748.x.PubMedCrossRef
22.
Gong Z, Luo QZ, Lin L, Su YP, Peng HB, Du K, Yu P, Wang SP: Association of MICA gene polymorphisms with liver fibrosis in schistosomiasis patients in the Dongting Lake region. Braz J Med Biol Res. 2012, 45: 222-229. 10.1590/S0100-879X2012007500024.PubMedPubMedCentralCrossRef
23.
Gaudieri S, Leelayuwat C, Tay GK, Townend DC, Dawkins RL: The major histocompatability complex (MHC) contains conserved polymorphic genomic sequences that are shuffled by recombination to form ethnic-specific haplotypes. J Mol Evol. 1997, 45: 17-23. 10.1007/PL00006194.PubMedCrossRef
24.
Salih HR, Rammensee HG, Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002, 169: 4098-4102.PubMedCrossRef
25.
Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A: Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003, 102: 1389-1396. 10.1182/blood-2003-01-0019.PubMedCrossRef
26.
Salih HR, Holdenrieder S, Steinle A: Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci. 2008, 13: 3448-3456.PubMedCrossRef
27.
Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V: Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia. 2004, 6: 558-568. 10.1593/neo.04316.PubMedPubMedCentralCrossRef
28.
Chalupny NJ, Rein-Weston A, Dosch S, Cosman D: Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun. 2006, 21: 175-181.CrossRef
29.
Chen Y, Cheng M, Tian Z: Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol. 2006, 3: 373-378.PubMed
30.
Schepis D, Damato M, Studahl M, Bergström T, Kärre K, Berg L: Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol. 2009, 69: 429-436. 10.1111/j.1365-3083.2009.02241.x.PubMedCrossRef
31.
Nolting A, Dugast AS, Rihn S, Luteijn R, Carrington MF, Kane K, Jost S, Toth I, Nagami E, Faetkenheuer G, Hartmann P, Altfeld M, Alter G: MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology. 2010, 406: 12-20. 10.1016/j.virol.2010.05.014.PubMedPubMedCentralCrossRef
32.
Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, Garcia-Iglesias T, Hernandez-Flores G, Del Toro-Arreola S: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008, 8: 16-10.1186/1471-2407-8-16.PubMedPubMedCentralCrossRef
33.
Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, Hayashi N: Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008, 99: 1643-1649. 10.1111/j.1349-7006.2008.00859.x.PubMedCrossRef
34.
Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR: Soluble MICA in malignant diseases. Int J Cancer. 2006, 118: 684-687. 10.1002/ijc.21382.PubMedCrossRef
35.
Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR: Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 2006, 55: 1584-1589. 10.1007/s00262-006-0167-1.PubMedCrossRef
36.
Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Stieber P, Nagel D, Peterfi A, Steinle A, Salih HR: Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007, 27: 2041-2045.PubMed
37.
Suárez-Alvarez B, López-Vázquez A, Baltar JM, Ortega F, López-Larrea C: Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant. 2009, 9: 251-257. 10.1111/j.1600-6143.2008.02526.x.PubMedCrossRef
38.
Zhao J, Jiang Y, Lei Y, Zou K, Wang C, Huang S, Yi F, Xia B: Functional MICA-129 polymorphism and serum levels of soluble MICA are correlated with ulcerative colitis in Chinese patients. J Gastroenterol Hepatol. 2011, 26: 593-598. 10.1111/j.1440-1746.2010.06524.x.PubMedCrossRef
39.
Boukouaci W, Busson M, Peffault de Latour R, Rocha V, Suberbielle C, Bengoufa D, Dulphy N, Haas P, Scieux C, Amroun H, Gluckman E, Krishnamoorthy R, Toubert A, Charron D, Socié G, Tamouza R: MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood. 2009, 114: 5216-5224. 10.1182/blood-2009-04-217430.PubMedCrossRef
40.
Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR, Grosse-Wilde H: Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol. 2007, 123: 114-120. 10.1016/j.clim.2006.11.007.PubMedCrossRef
41.
von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf IG, Brossart P, Cook G: Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother. 2010, 59: 829-839. 10.1007/s00262-009-0807-3.PubMedCrossRef
42.
Pagés F, Kroemer G: Prognostic impact of anticancer immune responses: an introduction. Semin Immunopathol. 2011, 33: 317-319. 10.1007/s00281-011-0278-4.PubMedCrossRef
43.
Tamaki S, Kawakami M, Ishitani A, Kawashima W, Kasuda S, Yamanaka Y, Shimomura H, Imai Y, Nakagawa Y, Hatake K, Kirita T: Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res. 2010, 30: 4097-5101.PubMed
44.
Hook CE, Telyatnikova N, Goodall JC, Braud VM, Carmichael AJ, Garcia-Suarez O, Martínez-Borra J, López-Vázquez A, Rodrigo L, Gonzalez S, López-Larrea C: Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis. Clin Exp Immunol. 2004, 138: 54-60. 10.1111/j.1365-2249.2004.02596.x.PubMedPubMedCentralCrossRef
45.
Fernández-Morera JL, Rodríguez-Rodero S, Lahoz C, Tuñon A, Astudillo A: Soluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing-remitting multiple sclerosis. Hum Immunol. 2008, 69: 235-240. 10.1016/j.humimm.2008.01.021.PubMedCrossRef
46.
Jensen H, Andresen L, Nielsen J, Christensen JP, Skov S: Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. PLoS One. 2011, 6: e23023-10.1371/journal.pone.0023023.PubMedPubMedCentralCrossRef
47.
Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S: In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One. 2007, 2: e518-10.1371/journal.pone.0000518.PubMedPubMedCentralCrossRef
48.
Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004, 114: 560-568.PubMedPubMedCentralCrossRef
49.
Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G: MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA. 2008, 105: 1285-1290. 10.1073/pnas.0711293105.PubMedPubMedCentralCrossRef
50.
Ibana JA, Aiyar A, Quayle AJ, Schust DJ: Modulation of MICA on the surface of Chlamydia trachomatis-infected endocervical epithelial cells promotes NK cell-mediated killing. FEMS Immunol. Med Microbiol. 2012, 65: 32-42.
Metadata
Title
Elevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patients
Authors
Xiaoxin Jiang
Ju-Fang Huang
Zhi Huo
Qiuqui Zhang
Yan Jiang
Xiaoping Wu
Yanwen Li
Guanmin Jiang
Leping Zeng
Xiao-Xin Yan
Ping Yu
Renxian Cao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2012
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-13-62

Other articles of this Issue 1/2012

BMC Immunology 1/2012 Go to the issue

Research article

Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates

Research article

Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1α, MIP-2, KC, CX3CL1 and TGF-β in wounded tissue

Research article

Variation in the IL1B, TNF and IL6 genes and individual susceptibility to prosthetic joint infection

Research article

Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules

Research article

Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum

Retraction Note

Retraction Note: The absence of MyD88 has no effect on the induction of alternatively activated macrophage during Fasciola hepatica infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits